Search
forLearn
5 / 801 resultslearn Pronalen Fibro-Actif
learn Cissus Quadrangularis
learn Setipiprant
learn Glucosamine HCI
Research
5 / 1000+ resultsresearch Peripheral Arterial Disease: Diagnosis and Management
PAD is common but often missed, needing lifestyle changes and medication for better outcomes.
research Peripheral Arterial Disease: Diagnosis and Management
Early recognition and treatment of Peripheral Arterial Disease is crucial to improve survival and health outcomes.
research MINOXIDIL-HAEMODYNAMIC AND CLINICAL EXPERIENCES WITH A NEW PERIPHERAL VASODILATOR
Minoxidil helps control blood pressure but has side-effects, so it's not for everyone.
research WISP-1 induced by mechanical stress contributes to fibrosis and hypertrophy of the ligamentum flavum through Hedgehog-Gli1 signaling
Targeting Hedgehog signaling may help treat ligamentum flavum fibrosis.
research Pleuropericardial effusion associated with minoxidil administration
Minoxidil can cause pericardial and pleural effusions with high protein content.
Community Join
5 / 1000+ resultscommunity Setipiprant/PGE2 feedbacks?
community Has anyone tried CB-01-03 aka Clascoterone?
Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.
community RESULTS: 1% Clascoterone Cream. (3 months Jan-Mar 2026)
community And just like that, everyone stopped talking about Clascoterone?
Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.
community Taking part in a Clascoterone Study
The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.